BioAge Labs, Inc.BIOA
What BioAge Labs, Inc. does.
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.
In January 2025, we announced the nomination of our lead program, BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor. BGE-102 has a distinct mechanism and binding site from other NLRP3 inhibitors in development with issued patents covering both composition of matter and claims for the unique binding site.
In December 2025, we announced that BGE-102 was well-tolerated in Single Ascending Dose (SAD) and initial Multiple Ascending Dose (MAD) cohorts, with a pharmacokinetic profile supporting once-daily oral dosing, strong target engagement and high brain penetration.
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | — | $0 | $9.0M |
| Net income | — | -$63.9M | -$71.1M | -$80.6M |
| Free cash flow | — | -$37.5M | -$51.9M | -$82.3M |
More on BIOA.
- BioAge Labs, Inc. summary
- BioAge Labs, Inc. financial statements
- BioAge Labs, Inc. key metrics
- BioAge Labs, Inc. health scores and style box
- BioAge Labs, Inc. earnings
- BioAge Labs, Inc. dividends
- BioAge Labs, Inc. valuation
- BioAge Labs, Inc. ownership and insiders
- BioAge Labs, Inc. peers
Figures from BioAge Labs, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.